Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4
Authors' conclusion
No clinically relevant differences were observed between the duration or characteristics of hypoglycemic events in efsitora and once-daily treatment groups in the QWINT-2, -3, and -4 trials.
Study context
- Population
- Adults with T2D in the QWINT-2, −3 and −4 trials3 trials
- Comparison
- Once-weekly efsitora vs once-daily basal insulin comparators
- Primary endpoint
- Median duration of hypoglycemia events, assessed with masked CGM
Methodological detailspooled across three phase 3 trials
- Pooled across three phase 3 trials
Primary result
As reported in the abstract
Median duration of hypoglycemic events
Level 1 and 2 [<70 mg/dL]: efsitora vs once-daily
40-42.5 vs 40 min
Level 2 [<54 mg/dL]: efsitora vs once-daily
35-39.9 vs 35 min
Further findings
Persistent-recurrent (PR) hypoglycemia
- Few incidences of PR hypoglycemia were reported for efsitora or once-daily comparators
Hypoglycemia contributing factors, characteristics and treatment methods
- No major descriptive differences between efsitora and once-daily groups
Original publication
Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4. Diabetes Res Clin Pract. Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →